Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 10;14(7):3175-3190.
doi: 10.18632/aging.204006. Epub 2022 Apr 10.

Burden of lymphoma in China, 1990-2019: an analysis of the global burden of diseases, injuries, and risk factors study 2019

Weiping Liu  1 , Jiangmei Liu  2 , Yuqin Song  1 , Xiaopei Wang  1 , Lan Mi  1 , Cai Cai  3 , Donglu Zhao  4 , Lijun Wang  2 , Jun Ma  4 , Jun Zhu  1
Affiliations

Burden of lymphoma in China, 1990-2019: an analysis of the global burden of diseases, injuries, and risk factors study 2019

Weiping Liu et al. Aging (Albany NY). .

Abstract

Background: China is facing an aggravating disease burden of lymphoma. However, accurate information about lymphoma burden at the national and provincial levels is limited.

Results: The estimated number of disability-adjusted life years were 86,171.85 for Hodgkin lymphoma and 1,306,247.77 for non-Hodgkin lymphoma with the age-standardized rates of 4.95 and 71.00, respectively, per 100,000 population. There were estimated 9,468 new cases and 2,709 Hodgkin lymphoma-related deaths, and 91,954 new cases and 44,310 non-Hodgkin lymphoma-related deaths. Older individuals had a higher lymphoma burden. The age-standardized disability-adjusted life year rate in men was approximately two-folds higher than that in women. Moreover, disparities in lymphoma burden were observed across the provinces. Between 1990 and 2019, the disability-adjusted life year number decreased by 57.8% for Hodgkin lymphoma, and increased by 100.9% for non-Hodgkin lymphoma.

Conclusion: Burden of lymphoma showed heterogeneous change patterns varied according to sex, age, and provinces, with a steady decrease in Hodgkin lymphoma and a significant increase in non-Hodgkin lymphoma during the past three decades.

Methods: Following the analytical strategy used in the Global Burden of Diseases, Injuries, and Risk Factors Study 2019, age-, sex-, and province-specific incidence, mortality, and prevalence of Hodgkin lymphoma and non-Hodgkin lymphoma were analyzed. Lymphoma burden was assessed by incidence, mortality, prevalence, and disability-adjusted life year.

Keywords: Hodgkin disease; incidence; lymphoma; mortality; non-Hodgkin.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST: The authors declare no conflicts of interest related to this study.

Figures

Figure 1
Figure 1
Burden of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) by age and sex in 2019. (A) number and age-standardized rates of disability-adjusted life years for HL, (B) age-standardized incidence rates for HL, (C) age-standardized mortality rates for HL, (D) number and age-standardized rates of disability-adjusted life years for NHL, (E) age-standardized incidence rates for NHL, (F) age-standardized mortality rates for NHL.
Figure 2
Figure 2
Age-standardized incidence rates (ASIR) and age-standardized mortality rates (ASMR) of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) by province of China, 2019. (A) ASIR of HL, (B) ASMR of HL, (C) ASIR of NHL, (D) ASMR of NHL.
Figure 3
Figure 3
Trends in burden of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) from 1990 to 2019. Change in the number and age-standardized rates of disability-adjusted life years for HL (A) and NHL (B), Change in age-standardized incidence and mortality rates for HL (C) and NHL (D).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer; 2020. https://gco.iarc.fr/today.
    1. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396:1204–22. 10.1016/S0140-6736(20)30925-9 - DOI - PMC - PubMed
    1. Liu W, Liu J, Song Y, Wang X, Zhou M, Wang L, Ma J, Zhu J, and Union for China Leukemia Investigators of the Chinese Society of Clinical Oncology, and Union for China Lymphoma Investigators of the Chinese Society of Clinical Oncology. Mortality of lymphoma and myeloma in China, 2004-2017: an observational study. J Hematol Oncol. 2019; 12:22. 10.1186/s13045-019-0706-9 - DOI - PMC - PubMed
    1. Liu W, Liu J, Song Y, Zeng X, Wang X, Mi L, Cai C, Wang L, Ma J, Zhu J, and Union for China Leukemia Investigators of the Chinese Society of Clinical Oncology, and Union for China Lymphoma Investigators of the Chinese Society of Clinical Oncology. Burden of lymphoma in China, 2006-2016: an analysis of the Global Burden of Disease Study 2016. J Hematol Oncol. 2019; 12:115. 10.1186/s13045-019-0785-7 - DOI - PMC - PubMed
    1. Pan R, Zhu M, Yu C, Lv J, Guo Y, Bian Z, Yang L, Chen Y, Hu Z, Chen Z, Li L, Shen H, and China Kadoorie Biobank Collaborative Group. Cancer incidence and mortality: A cohort study in China, 2008-2013. Int J Cancer. 2017; 141:1315–23. 10.1002/ijc.30825 - DOI - PubMed